SecurityAZN / AstraZeneca Plc
InstitutionEnvestnet Asset Management Inc
Shares232,184
Value $ 8,152,000
Related 046353AB4 / Astrazeneca 5.9% Senior Notes 9/15/17
046353AF5 / Astrazeneca Plc 1.95% 09/18/19
046353AG3 / Astrazeneca Plc 4.00% 09/18/42
046353AA6 / Astrazeneca Plc 5.40% Notes 06/01/2014
046353AD0 / Astrazeneca Plc 6.45% Senior Notes 9/15/37
98934KAB6 / Zeneca Wilmington Inc Guaranteed Debentures 7% 11/15/23

Envestnet Asset Management Inc reports 2.02% decrease in ownership of AZN / AstraZeneca Plc

August 10, 2018 - Envestnet Asset Management Inc has filed a 13F-HR form disclosing ownership of 232,184 shares of AstraZeneca Plc (NYSE:AZN) with total holdings valued at $8,152,000 USD as of June 30, 2018. Envestnet Asset Management Inc had filed a previous 13F-HR on May 09, 2018 disclosing 236,982 shares of AstraZeneca Plc at a value of $8,305,000 USD. This represents a change in shares of -2.02 percent and a change in value of -1.84 percent during the quarter.

Other investors with positions similar to Envestnet Asset Management Inc include Voloridge Investment Management, Llc, Keating Investment Counselors Inc, Pictet North America Advisors SA, Skba Capital Management Llc, Bb&t Securities, Llc, and Glenmede Trust Co Na.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 35.08 232,184 -2.02 8,152 -1.84 -168 15 0.18
2018-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 34.87 236,982 -63.33 8,305 -62.97 -14,274 153 0.68
2017-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 34.29 646,306 -0.24 22,426 2.18 -52 530 2.42
2017-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 33.98 647,829 -1.30 21,948 -1.91 -289 -138 -0.62
2017-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 32.61 656,339 0.41 22,375 9.93 87 1,935 9.51
2017-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 29.23 653,672 20.31 20,353 37.15 3,225 2,288 15.42
2016-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 30.09 543,313 -23.54 14,840 -36.45 -5,033 -3,477 -14.89
2016-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 31.52 710,599 -0.05 23,350 8.79 -11 1,897 8.84
2016-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 29.18 710,958 5.38 21,464 12.98 1,060 1,406 7.40
2016-03-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 31.06 674,632 3.87 18,998 -13.85 780 -3,833 -17.38
2015-12-31 13F-HR ASTRAZENECA SPONSORED ADR 046353108 32.88 649,526 7.49 22,051 14.68 1,488 1,335 6.94
2015-09-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 47.76 604,265 102.74 19,228 1.26 14,627 -14,387 -75.77
2015-06-30 13F-HR ASTRAZENECA SPONSORED ADR 046353108 66.07 298,042 44.77 18,988 34.78 6,089 -1,189 -8.44
2015-03-31 13F-HR ASTRAZENECA ADR 046353108 69.49 205,877 8,248.62 14,088 7,996.55 14,136 -222 -127.54
2014-12-31 13F-HR AstraZeneca COM 046353108 70.87 2,466 26.27 174 25.18 36 -1 -0.97
2014-09-30 13F-HR AstraZeneca COM 046353108 72.81 1,953 -10.25 139 -14.20 -16 -7 -4.17
2014-06-30 13F-HR * ASTRAZENECA ADR 046353108 2,176 162

Related SEC Filings

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment)

2018-02-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AZN / AstraZeneca Plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009895292_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) ASTRAZENECA PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DCL2 -------------------------------------------------------- (SEDOL Number) December 31, 2017 --------------------------------------------------------

AstraZeneca SEC SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-02-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ASTRAZENECA PLC (Name of Issuer) Ordinary Shares (Title of Class of Securities) G0593M107 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder o (0-1)

Related News Stories

Healthcare 16-24% Target Net Gains Pace WallStars For October

2018-10-15 seekingalpha
Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides. (34-0)

3 Large-Cap Pharma Stocks Performing Better Than Industry

2018-10-12 zacks
The Zacks Large-Cap Pharma industry, a 14 medical stock group, has gained 5.4% in the year so far. This industry also features among the top 9% of the 256 Zacks-ranked industries. (9-0)

J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

2018-10-12 zacks
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its blood thinner, Xarelto. The drug is now approved for reduction in risk of major cardiovascular (“CV”) events including CV death, myocardial infarction (“MI”) and stroke, in patients with chronic coronary or peripheral artery disease (CAD/PAD). (16-0)

PhaseBio IPO: Data To Be Released In 2018 And 2020

2018-10-12 seekingalpha
PhaseBio is a clinical-stage biopharmaceutical company developing treatments for orphan diseases. With a specialization on the cardiopulmonary space, the company has two product candidates, PB2452 and PB1046. (3-0)

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

2018-10-11 zacks
On Oct 10, we issued an updated research report on Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . (16-0)



CUSIP: 046353108